Colgate-Palmolive Company (CL) Stock Price & How to Invest

Colgate-Palmolive is a global consumer-staples company that makes everyday household and personal-care products. It is a worldwide leader in oral care, where its Colgate-branded toothpaste, toothbrushes, and mouthwash hold a leading global share, and it also sells personal care (soaps, body wash, deodorants under brands like Palmolive, Softsoap, Irish Spring, and Sanex), home care (dish and surface cleaners such as Palmolive and Ajax), and pet nutrition through its Hill's Pet Nutrition business (Science Diet and Prescription Diet). Colgate makes money by selling these branded, frequently repurchased products at scale across more than 200 countries and territories, with a particularly large presence in emerging markets. Its competitive advantages come from powerful brands, vast distribution, and pricing power on staple goods. Headquartered in New York City, Colgate is a defensive, dividend-paying company whose products people buy regardless of the economic cycle.

Colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist. It faces intense competition from Procter and Gamble, Unilever, and private-label brands, plus pressure from retailers. Heavy emerging-market exposure brings currency volatility that can erode reported results. Input-cost inflation, the rise of private label during cost-of-living squeezes, and the challenge of sustaining pricing without losing volume all weigh on the outlook. The defensive premium valuation can also compress when investors rotate toward higher-growth or cyclical names.

20 analysts publish price targets on CL, averaging $97.65 against a $92.60 price as of July 2026, or +5.5%. The published targets run from $85.00 to $110.00, a narrow spread, and the ratings split 13 buy, 7 hold, 1 sell. Over the last six months there have been 9 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CL forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Colgate-Palmolive Company. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Oral-care leadership and emerging markets. Colgate holds a leading global share in toothpaste and a strong position in toothbrushes and mouthwash, with deep penetration in emerging markets across Latin America, Africa, and Asia. The most optimistic published target, $110.00, assumes this works close to its best case.

The case against. Colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist. The most pessimistic target, $85.00, is roughly what CL is worth if this bites instead.

Read the full bull and bear case on CL, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Colgate-Palmolive Company's investor relations page or your broker.

• Revenue (TTM): ~$20 billion
• Operating margin: ~20-21%
• Net income (TTM): ~$2.7 billion
• Dividend yield: ~2-2.5% (Dividend King)
• P/E (TTM): ~22-26x, a defensive premium
• Free cash flow: strong and consistent
• Segments: Oral, Personal and Home Care; Hill's Pet Nutrition

Colgate trades at a premium consumer-staples multiple that reflects its defensive, recession-resistant cash flows, leading oral-care brands, the growth of Hill's, and a multi-decade dividend-raising record. The valuation premium is the market paying for stability and pricing power, balanced against the reality of slow underlying volume growth in mature categories.

If you want CL exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses CL naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to CL: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (USO, PDBC, UCO), which spreads the position across many companies. Or build it into a focused thematic portfolio, so CL sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Colgate-Palmolive (CL) is a Dividend King whose moat rests on dominant oral-care brands, vast distribution across 200-plus countries, and pricing power on frequently repurchased staples, with Hill's adding premium pet-nutrition growth. In a portfolio it acts as a low-volatility defensive anchor that tends to hold up in downturns, trading growth for stability and a steadily rising dividend.

Whether CL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CL a buy or a sell?, and where the stock could go from here in the CL stock forecast.

For income investors, whether CL pays a dividend and how the payout looks is covered in does CL pay a dividend? And to weigh CL against a peer, read the full side-by-side comparisons: CL vs ABT and CL vs COST.